Reproductive Medicine Associates of New York, New York, New York; Department of Obstetrics and Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai West, New York, New York.
Reproductive Medicine Associates of New York, New York, New York.
Fertil Steril. 2019 Jun;111(6):1177-1185.e3. doi: 10.1016/j.fertnstert.2019.02.024. Epub 2019 Apr 24.
To investigate whether the duration of estrogen administration before euploid embryo transfer affects clinical outcome.
Retrospective cohort study.
Private, academic fertility center.
PATIENT(S): Patients (n = 1,439) undergoing autologous freeze-only in vitro fertilization with preimplantation genetic testing (PGT) followed by endometrial preparation with estrogen and progesterone in a frozen, euploid blastocyst transfer cycle.
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): Primary outcome was live birth, and secondary outcomes included implantation, clinical pregnancy, early pregnancy loss, live birth, infant birthweight, low birth weight, infant gestational age at delivery, and preterm birth.
RESULT(S): The duration of estrogen administration (mean: 17.5 ± 2.9 days; range: 10-36 days) before frozen embryo transfer did not impact implantation (odds ratio [OR] 0.99; 95% confidence interval [CI], 0.95-1.03), clinical pregnancy (OR 0.98; 95% CI, 0.94-1.01), early pregnancy loss (OR 1.03; 95% CI, 0.95-1.12), or live birth (OR 0.99; 95% CI, 0.95-1.03). The duration of estrogen exposure did not affect infant birthweight (in grams) (β= -10.65 ± 8.91) or the odds of low birth weight (OR 0.87; 95% CI, 0.68-1.13). For every additional day of estrogen administration, we observed a reduction in gestational age at delivery (in weeks) (β= -0.07 ± 0.03), but the odds of preterm delivery were not affected (OR 1.05; 95% CI, 0.95-1.17).
CONCLUSION(S): Variation in the duration of estradiol supplementation before progesterone initiation does not impact frozen, euploid blastocyst transfer outcome. The duration of estrogen administration was inversely correlated with gestational age at delivery, but this did not translate into an increase in preterm delivery. Further studies are required on the downstream effects of endometrial preparation on the placental-endometrium interface.
探讨胚胎移植前雌激素给药时间对临床结局的影响。
回顾性队列研究。
私立学术生育中心。
(n=1439)接受自体冷冻只试管婴儿,并在植入前遗传学检测(PGT)后,通过雌激素和孕激素进行子宫内膜准备,在冷冻、整倍体囊胚转移周期中进行。
无。
主要结局为活产,次要结局包括着床、临床妊娠、早期妊娠丢失、活产、婴儿出生体重、低出生体重、婴儿分娩时的胎龄和早产。
胚胎移植前雌激素给药时间(平均值:17.5±2.9 天;范围:10-36 天)不影响着床(比值比[OR]0.99;95%置信区间[CI]0.95-1.03)、临床妊娠(OR0.98;95%CI0.94-1.01)、早期妊娠丢失(OR1.03;95%CI0.95-1.12)或活产(OR0.99;95%CI0.95-1.03)。雌激素暴露时间不影响婴儿出生体重(克)(β=-10.65±8.91)或低出生体重的几率(OR0.87;95%CI0.68-1.13)。每增加一天的雌激素治疗,我们观察到分娩时的胎龄(周)减少(β=-0.07±0.03),但早产的几率没有受到影响(OR1.05;95%CI0.95-1.17)。
在开始使用孕激素之前,雌二醇补充的时间长短变化不会影响冷冻、整倍体囊胚移植的结局。雌激素给药时间与分娩时的胎龄呈负相关,但这并没有导致早产的增加。需要进一步研究子宫内膜准备对胎盘-子宫内膜界面的下游影响。